How Investors Are Reacting To CME Group (CME) Partnering With FanDuel on Retail Event-Based Contracts

• CME Group and FanDuel recently announced a partnership to launch new event-based financial contracts, allowing FanDuel’s extensive U.S. customer base to access regulated products tied to indices, commodities, cryptocurrencies, and key economic indicators for as little as US$1 per contract.
• This alliance highlights the growing convergence of traditional finance and retail-focused platforms, potentially expanding CME Group’s reach beyond institutional clients to millions of retail users.
• Next, we’ll explore how the launch of low-cost, event-based contracts through FanDuel could reshape CME Group’s growth narrative and retail market positioning.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

CME Group Investment Narrative Recap

To be a shareholder in CME Group, you need to believe in its pace-setting role within regulated derivatives markets and the ongoing demand for transparent, liquid risk management tools. The recent FanDuel partnership opens a pathway to new retail audiences, but whether this transforms near-term growth depends on regulatory clearance and actual uptake, at present, neither the most important short-term catalysts nor the largest risks, such as declining volatility or evolving competitive threats, are fundamentally altered.

Of the company's recent announcements, the March 2025 initiative with Google Cloud stands out for its focus on secure wholesale payments and asset tokenization. Though separate from the FanDuel alliance, this development addresses another key growth driver: expanding technology infrastructure and services beyond traditional exchange operations, reinforcing CME’s position against both emerging fintech rivals and established peer platforms.

Yet, for all the promise, potential regulatory shifts affecting retail derivatives access remain a real concern for CME Group investors, especially if...

Read the full narrative on CME Group (it's free!)

CME Group's narrative projects $7.3 billion in revenue and $4.2 billion in earnings by 2028. This requires 4.1% yearly revenue growth and a $0.5 billion earnings increase from the current earnings of $3.7 billion.

Uncover how CME Group's forecasts yield a $283.11 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Five value estimates from the Simply Wall St Community set CME Group’s fair value anywhere between US$175.71 and US$283.11 per share. While investor views display this broad spectrum, the possibility of regulatory tightening around retail-focused contracts could meaningfully affect both revenue projections and the company’s market position, explore several viewpoints to inform your next steps.

Explore 5 other fair value estimates on CME Group - why the stock might be worth as much as $283.11!

Build Your Own CME Group Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your CME Group research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free CME Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CME Group's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com